AstraZeneca’s Imfinzi Scores Neoadjuvant/Adjuvant NSCLC Two-fer At AACR
The PD-L1 inhibitor showed efficacy in the neoadjuvant/adjuvant setting, where Merck is developing Keytruda as well. BMS’s Opdivo was the first to win approval in neoadjuvant NSCLC.
You may also be interested in...
A positive showing by Bristol Myers Squibb’s checkpoint inhibitor Opdivo in non-small cell lung cancer could broaden its use, though much depends on the magnitude of the hit.
AstraZeneca’s Imfinzi is playing catch-up to other PD1/L1 targeting agents in neoadjuvant/adjuvant NSCLC with new data from AEGEAN, but new survival data for Tagrisso from ADAURA consolidate its dominance in early-stage EGFR positive disease.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker